Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P cut its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 9.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,605 shares of the company’s stock after selling 1,664 shares during the period. Martingale Asset Management L P’s holdings in Vaxcyte were worth $1,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC lifted its holdings in shares of Vaxcyte by 3.6% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company’s stock valued at $146,093,000 after buying an additional 66,940 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Vaxcyte by 47.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock valued at $148,075,000 after acquiring an additional 419,600 shares during the period. Novo Holdings A S lifted its holdings in Vaxcyte by 12.4% in the second quarter. Novo Holdings A S now owns 950,000 shares of the company’s stock valued at $71,734,000 after acquiring an additional 105,000 shares during the period. Maverick Capital Ltd. lifted its holdings in Vaxcyte by 93.7% in the second quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock valued at $51,944,000 after acquiring an additional 332,777 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Vaxcyte by 14.3% in the 2nd quarter. American Century Companies Inc. now owns 527,594 shares of the company’s stock valued at $39,839,000 after purchasing an additional 65,870 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Grant Pickering sold 2,366 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. The trade was a 1.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the sale, the senior vice president now owns 12,723 shares of the company’s stock, valued at $1,369,885.41. This trade represents a 28.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 102,464 shares of company stock worth $11,455,576. 3.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PCVX. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Mizuho upped their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Jefferies Financial Group upped their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. BTIG Research upped their price target on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Leerink Partners upped their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $94.34 on Monday. The business has a 50 day simple moving average of $105.60 and a two-hundred day simple moving average of $90.49. Vaxcyte, Inc. has a 12 month low of $50.04 and a 12 month high of $121.06. The stock has a market capitalization of $11.76 billion, a P/E ratio of -20.51 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the company earned ($0.91) earnings per share. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.